Visual side effects of pegylated interferon during therapy for chronic hepatitis C infection

Journal of Clinical Gastroenterology

Volumn 38, Issue 8, 2004, Pages 717-722

  Willson, Richard A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hepatitis C; Ocular toxicity; Pegylated interferon

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; DRUG EFFICACY; EXOPHTHALMOS; EYE PAIN; EYE TOXICITY; HEPATITIS C; HUMAN; MALE; OPHTHALMOLOGY; OPTIC NERVE DISEASE; PRIORITY JOURNAL; RETINOPATHY; SIDE EFFECT; VISUAL DISORDER; VISUAL IMPAIRMENT;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; VISION DISORDERS;

EID: 4143101297     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000135897.30038.16     Document Type: Article

References (35)

1. Vinayek R, Shakil AO. Adverse events associated with interferon alfa therapy in patients with chronic viral hepatitis. Viral Hepatitis Review. 1997;3:167-177.
2. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36:S237-S244.
3. Glue P, Fang JWS, Rouzier-Panis R, et al. Pegylated interferon alfa-2b: pharmacokinetics, pharmocodynamics, safety and preliminary efficacy data. Clin Pharmacol Ther. 2000;68:556-567.
4. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
5. Hayasaka S, Nagaki Y, Matsumoto M, et al. Interferon associated retinopathy. Br J Ophthalmol. 1998;82:323-325.
6. Farkkila M, Livanainen M, Roine R, et al. Neurotoxic and other side effects of high dose interferon in ALS. Acta Neurol Scand. 1984;70:42-46.
7. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon associated retinopathy. Arch Ophalmol. 1993;111:350-356.
8. Manesis EK, Petrou C, Brouzas D, et al. Optic tract neuropathy complicating low dose interferon treatment. J Hepatol. 1994;21:474-477.
9. Nao-i N, Matuura Y, Sawada A, et al. Prospective study of the incidence of interferon-induced retinopathy in patients with chronic hepatitis. Ophthalmology. 1994;101 (Suppl):119. (Abstract)
10. Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis C. Br J Opthalmol. 1994;78:238.
11. Yamada H, Mizobuchi K, Isogai Y, et al. Acute onset of ocular complications with interferon. Lancet. 1994;343:914.
12. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with interferon alfa therapy for chronic active hepatitis C. Am J Gastroenterol. 1994;89:2054-2056.
13. Ene L, Gehenot M, Horsmans Y, et al. Transient blurred vision after interferon for chronic hepatitis C. Lancet. 1994;344:827-828.
14. Purvin VA. Anterior ischemic optic neuropathy secondary to interferon. Arch Opthalmol. 1995;113:1041-1044.
15. Shahidullah AB, Cerulli MA, Berman DH. Interferon may cause retinopathy during hepatitis therapy. Am J Gastroenterol. 1995;90:1543.
16. Hayasaka S, Fujii M, Yamamoto Y, et al. Retinopathy and subconjunctional hemorrhage in patients with chronic viral hepatitis receiving interferon alfa. Br J Ophthalmol. 1995;79:150-152.
17. Kawano T, Shigehira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol. 1996;91:309-313.
18. Kuga K, Hasumura S, Nagamori S, et al. Intraocular hemorrhage developing during interferon therapy. Intern Med. 1996;35:15-18.
19. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high dose interferon therapy for chronic hepatitis C. J Hepatol. 1996;25:283-291.
20. Chambers RB, Downie A, Foote B, et al. Interferon associated retinopathy. J Am Osteopath Assoc. 1997;97:43-45.
21. Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alfa-interferon treatment in chronic viral hepatitis. Hepatology. 1998;27:1421-1427.
22. Deeb LS, Khouri AS, Hall CE, et al. Interferon and ribavirin associated retinopathy in patients with hepatitis C. Hepatology. 1998;28:371A.
23. Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alpha-2b treatment for malignant melanoma. Lancet. 1999;353:1326.
24. Norcia F, DiMaria A, Prandini F, et al. Natural interferon therapy: Optic nerve ischemic damage? Ophthalmologica. 1999;218:339-340.
25. Nadir A, Amin A, Chalisa AN, et al. Retinal vein thrombosis associated with hepatitis C: a case series and review of the literature. J Viral Hepat. 2000;7:466-470.
26. Suzuki T, Yonemura K, Miyaji T, et al. Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferatiave glomerulonephritis. Intern Med. 2001;40:708-712.
27. Esmaeli B, Koller C, Papadopoulos N, et al. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology. 2001;108:858-860.
28. Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa 2-b therapy. Am J Ophthalmol. 2001;131:782-787.
29. Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol. 2001;85:1171-1173.
30. Perlemuter G, Bodaghi B, Le Hoang P, et al. Visual loss during interferon-alfa therapy in hepatitis C virus infection. J Hepatol. 2002;37:701-702.
31. Zuber J, Martinez F, Droz D, et al. Alpha-interferon-associated thrombotic microangiopathy. A clinicopathologic study of 8 patients and review of the literature. Medicine. 2002;81:321-331.
32. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.
33. Kraus MR, Schafer A, Scheurlen M. Paroxetine for the prevention of depression-induced by interferon alfa. N Engl J Med. 2001;345:375-376.
34. Iyoda K, Kato M, Nakagawa T, et al. Thrombotic thrombocytopenic purpura developed suddenly during interferon treatment for chronic hepatitis C. J Gastroenterol. 1998;33:588-592.
35. Ubara Y, Hara S, Takedatu H, et al. Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron. 1998;80:107-108.